Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LKA651 + ranibizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravitreal
01
Overview
LKA651 + ranibizumab is a combination therapy used in the treatment of diabetic macular edema (DME). The combination involves intravitreal injections of LKA651 (at 1 mg) with ranibizumab (at 0.3 mg for U.S. sites or 0.5 mg for ex-U.S. sites). The therapy is administered every 4 weeks for a total of 3 doses in the treatment phase.
- Brand names
- LKA651 + Lucentis
02
Targets
Beyond the preview
Go deeper on LKA651 + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LKA651 + ranibizumab.